Summary

Persistence Market Research has recently released a comprehensive report on the global Syndromic Multiplex Diagnostics Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Syndromic Multiplex Diagnostics Market Size (2025E): US$ 2,646.1 Mn
• Projected Market Value (2032F): US$ 3,629.3 Mn
• Global Market Growth Rate (CAGR 2025 to 2032): 4.6%

Syndromic Multiplex Diagnostics Market – Report Scope:

The syndromic multiplex diagnostics market focuses on molecular diagnostic tools capable of detecting multiple pathogens from a single patient sample, offering rapid and accurate results. These diagnostics are especially valuable in identifying infections related to respiratory, gastrointestinal, and central nervous systems. The increasing demand for rapid, accurate, and cost-effective diagnostic solutions in clinical settings is significantly fueling the growth of this market. Advances in molecular biology, growing awareness regarding infectious disease management, and the emergence of novel pathogens are reshaping the diagnostics landscape.

Market Growth Drivers:

The global syndromic multiplex diagnostics market is witnessing significant momentum, primarily driven by the growing prevalence of infectious diseases, the rise in antimicrobial resistance, and the need for early, accurate diagnosis. The ability of syndromic panels to identify multiple pathogens simultaneously reduces the time to diagnosis and enhances treatment efficacy. The increasing adoption of molecular diagnostics in hospitals and diagnostic laboratories, along with rising investments in healthcare infrastructure across developing regions, is also contributing to market growth. Moreover, the growing demand for point-of-care diagnostic solutions and increasing awareness about personalized medicine are fostering adoption globally.

Market Restraints:

Despite the promising outlook, certain challenges may hamper the growth of the syndromic multiplex diagnostics market. High costs associated with syndromic testing platforms and consumables can limit their widespread adoption, particularly in resource-constrained settings. Regulatory complexities and variability in reimbursement policies across different countries also create hurdles for market penetration. Additionally, concerns related to data interpretation, test sensitivity, and the potential for overdiagnosis could restrict clinical utilization in some cases.

Market Opportunities:

The syndromic multiplex diagnostics market presents vast growth opportunities, especially with continued technological advancements and automation in molecular testing. The expansion of applications beyond infectious diseases—such as oncology and genetic testing—provides new avenues for development. Emerging markets in Asia-Pacific, Latin America, and the Middle East & Africa offer untapped potential due to improving healthcare access and growing awareness. Moreover, strategic collaborations with healthcare institutions and ongoing R&D investments aimed at developing cost-effective and portable diagnostic devices will enhance the market’s competitive edge and global reach.

Key Questions Answered in the Report:

• What are the primary factors driving the global syndromic multiplex diagnostics market’s growth?
• Which regions and diagnostic segments are witnessing the highest demand?
• How are technological innovations shaping the diagnostic landscape?
• Who are the major players in the syndromic multiplex diagnostics market, and what strategies are they employing?
• What future trends are likely to define the market trajectory?

Competitive Intelligence and Business Strategy:

Leading companies in the syndromic multiplex diagnostics market, such as Abbott Laboratories, bioMérieux, Thermo Fisher Scientific, Inc., Hologic, Inc., and F. Hoffmann-La Roche Ltd., are prioritizing R&D to launch advanced, rapid diagnostic solutions. Companies are also forming strategic alliances to broaden their product offerings and strengthen their global distribution networks. Continuous product innovation, regulatory approvals, and expanding indications for multiplex tests remain key strategic focus areas. The development of portable, user-friendly devices tailored for point-of-care use is also a central area of investment for enhancing market reach.

Companies Covered in This Report:

• Abbott Laboratories
• bioMérieux
• Thermo Fisher Scientific, Inc.
• Hologic, Inc.
• F. Hoffmann-La Roche Ltd.
• DiaSorin S.p.A (Luminex Corporation)
• QIAGEN N.V.
• Applied BioCode
• Becton, Dickinson and Company (BD)
• Hologic, Inc.

Market Segmentation

By Type:

• Respiratory
• Gastrointestinal
• Central Nervous System
• Others

By End Use:

• Hospitals
• Diagnostic Laboratories
• Others

By Region:

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Syndromic Multiplex Diagnostics Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-economic Factors
2.3.1. Health Insurance Penetration and Reimbursement Policies
2.3.2. Government Healthcare Spending and Preparedness Initiatives
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Type Adoption Analysis
3.3. Value Chain Analysis
3.4. Key Deals and Mergers
3.5. PESTLE Analysis
3.6. Porter’s Five Force Analysis
4. Global Syndromic Multiplex Diagnostics Market Outlook:
4.1. Key Highlights
4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
4.2.2. Market Size (US$ Mn) Analysis and Forecast, 2025-2032
4.3. Global Syndromic Multiplex Diagnostics Market Outlook: Type
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Mn) Analysis, By Type, 2019-2024
4.3.3. Market Size (US$ Mn) Analysis and Forecast, By Type, 2025-2032
4.3.3.1. Respiratory
4.3.3.2. Gastrointestinal
4.3.3.3. Central Nervous System
4.3.3.4. Others
4.3.4. Market Attractiveness Analysis: Type
4.4. Global Syndromic Multiplex Diagnostics Market Outlook: End Use
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Mn) Analysis, By End Use, 2019-2024
4.4.3. Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
4.4.3.1. Hospitals
4.4.3.2. Diagnostic Laboratories
4.4.3.3. Others
4.4.4. Market Attractiveness Analysis: End Use
5. Global Syndromic Multiplex Diagnostics Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
5.3. Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Syndromic Multiplex Diagnostics Market Outlook:
6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
6.2.1. By Country
6.2.2. By Type
6.2.3. By End Use
6.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
6.3.1. U.S.
6.3.2. Canada
6.4. Market Size (US$ Mn) Analysis and Forecast, By Type, 2025-2032
6.4.1. Respiratory
6.4.2. Gastrointestinal
6.4.3. Central Nervous System
6.4.4. Others
6.5. Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
6.5.1. Hospitals
6.5.2. Diagnostic Laboratories
6.5.3. Others
6.6. Market Attractiveness Analysis
7. Europe Syndromic Multiplex Diagnostics Market Outlook:
7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
7.2.1. By Country
7.2.2. By Type
7.2.3. By End Use
7.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Market Size (US$ Mn) Analysis and Forecast, By Type, 2025-2032
7.4.1. Respiratory
7.4.2. Gastrointestinal
7.4.3. Central Nervous System
7.4.4. Others
7.5. Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
7.5.1. Hospitals
7.5.2. Diagnostic Laboratories
7.5.3. Others
7.6. Market Attractiveness Analysis
8. East Asia Syndromic Multiplex Diagnostics Market Outlook:
8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
8.2.1. By Country
8.2.2. By Type
8.2.3. By End Use
8.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Market Size (US$ Mn) Analysis and Forecast, By Type, 2025-2032
8.4.1. Respiratory
8.4.2. Gastrointestinal
8.4.3. Central Nervous System
8.4.4. Others
8.5. Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
8.5.1. Hospitals
8.5.2. Diagnostic Laboratories
8.5.3. Others
8.6. Market Attractiveness Analysis
9. South Asia & Oceania Syndromic Multiplex Diagnostics Market Outlook:
9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
9.2.1. By Country
9.2.2. By Type
9.2.3. By End Use
9.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Market Size (US$ Mn) Analysis and Forecast, By Type, 2025-2032
9.4.1. Respiratory
9.4.2. Gastrointestinal
9.4.3. Central Nervous System
9.4.4. Others
9.5. Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
9.5.1. Hospitals
9.5.2. Diagnostic Laboratories
9.5.3. Others
9.6. Market Attractiveness Analysis
10. Latin America Syndromic Multiplex Diagnostics Market Outlook:
10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
10.2.1. By Country
10.2.2. By Type
10.2.3. By End Use
10.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Market Size (US$ Mn) Analysis and Forecast, By Type, 2025-2032
10.4.1. Respiratory
10.4.2. Gastrointestinal
10.4.3. Central Nervous System
10.4.4. Others
10.5. Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
10.5.1. Hospitals
10.5.2. Diagnostic Laboratories
10.5.3. Others
10.6. Market Attractiveness Analysis
11. Middle East & Africa Syndromic Multiplex Diagnostics Market Outlook:
11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
11.2.1. By Country
11.2.2. By Type
11.2.3. By End Use
11.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Market Size (US$ Mn) Analysis and Forecast, By Type, 2025-2032
11.4.1. Respiratory
11.4.2. Gastrointestinal
11.4.3. Central Nervous System
11.4.4. Others
11.5. Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
11.5.1. Hospitals
11.5.2. Diagnostic Laboratories
11.5.3. Others
11.6. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2025
12.2. Market Type
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Abbott Laboratories
12.3.1.1. Overview
12.3.1.2. Segments and Types
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. bioMérieux
12.3.3. Thermo Fisher Scientific, Inc.
12.3.4. Hologic, Inc.
12.3.5. F. Hoffmann-La Roche Ltd.
12.3.6. DiaSorin S.p.A (Luminex Corporation)
12.3.7. QIAGEN N.V.
12.3.8. Applied BioCode
12.3.9. Becton, Dickinson and Company (BD)
12.3.10. Hologic, Inc.
12.3.11. Others
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations